Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 100 mg, cellulosum microcristallinum, lactosum monohydricum 108.68 mg, carboxymethylamylum natricum a corresp. natrium 0.64 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (flavum), e 172 (rubrum), e 132, pro compresso obducto. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 150 mg, cellulosum microcristallinum, lactosum monohydricum 163.02 mg, carboxymethylamylum natricum a corresp. natrium 0.96 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 200 mg, cellulosum microcristallinum, lactosum monohydricum 217.36 mg, carboxymethylamylum natricum a corresp. natrium 1.28 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - tabletten und ontozry 25 mg, filmtabletten - i) ontozry 12.5 mg, tablette: cenobamatum 12.5 mg, cellulosum microcristallinum, lactosum monohydricum 39.67 mg, carboxymethylamylum natricum a corresp. natrium 0.16 mg, silica colloidalis anhydrica, magnesii stearas, pro compresso. ii) ontozry 25 mg, filmtablette: cenobamatum 25 mg, cellulosum microcristallinum, lactosum monohydricum 79.34 mg, carboxymethylamylum natricum a corresp. natrium 0.32 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (flavum), e 172 (rubrum), e 132, pro compresso obducto. - antieptileptikum - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - patioromer sorbitex calcium - hyperkaliämie - medikamente zur behandlung von hyperkalemia und hyperphosphatämie - veltassa ist indiziert zur behandlung von hyperkaliämie bei erwachsenen.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

wabosan arzneimittelvertriebs gmbh - lithiumcarbonat - lithium

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

essential pharma switzerland gmbh - lithium - tabletten - lithii carbonas 400 mg corresp. lithium 10.8 mmol, acaciae gummi dispersione desiccatum, mannitolum, natrii laurilsulfas, glyceroli distearas, magnesii stearas, maydis amylum, carboxymethylamylum natricum a, pro compresso corresp. natrium 0.211 mg. - manisch depressive zustände - synthetika

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

essential pharma (m) - lithium carbonate - filmtablette - 250 mg - lithium carbonate 250 mg - lithium

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

essential pharma (m) - lithium carbonate - filmtablette - 400 mg - lithium carbonate 400 mg - lithium

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.